The microbiota as a dynamic ecosystem
The gut microbiota is not simply the collection of microorganisms inhabiting the digestive tract. It is a dynamic ecosystem in which bacteria, metabolites, the intestinal mucosa, the immune system, and the host organism continuously communicate.
In this system, probiotics are live microorganisms that, when administered in adequate amounts, can confer a health benefit to the host. Their use, however, cannot be reduced to the simple idea of “adding good bacteria.”
Modern research has indeed revealed a much more complex reality: two probiotics belonging to the same genus may have different effects, and the same strain may prove useful in one condition but not another.
This strain specificity represents one of the most important elements for correctly interpreting the scientific literature. The number of microorganisms present in a formulation alone is therefore not sufficient to predict its efficacy.
How probiotics work
The mechanisms through which probiotics may interact with the organism are manifold.
One of the main ones involves ecological competition with other microorganisms. Some strains can modify the conditions of the intestinal environment, compete for nutrients and adhesion sites, and produce substances capable of hindering the growth of unwanted microorganisms.
A second level involves the intestinal barrier. Some probiotics can influence tight junction proteins and the interaction between the epithelium, mucus, and microbiota, helping to maintain the integrity of the mucosa.
There is also an interaction with the immune system. Intestinal microorganisms and their metabolites can modulate the activity of immune cells and the production of inflammatory mediators.
Another mechanism is represented by the production or modulation of metabolites, including short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate. These molecules participate in communication between the microbiota and the host organism and can influence the intestinal epithelium, metabolism, and immune response.
Constipation: a possible, but not universal, effect
Constipation is one of the areas in which probiotics have been studied to modify bowel movement frequency, stool consistency, and symptoms.
A 2024 meta-analysis comprising 17 studies and 1,256 adult participants with functional constipation found an increase in bowel movement frequency and an improvement in stool consistency, as well as a reduction in symptoms. However, heterogeneity among the studies was high, and the quality of the evidence was judged to be low to very low.
This finding is important because it prevents the statement “probiotics help with constipation” from becoming a general rule. The response depends on the formulation and the strain used.
Antibiotic-associated diarrhea
The alteration of the microbiota caused by antibiotic therapy represents one of the scenarios in which the use of specific probiotics has been most extensively studied.
A meta-analysis published in 2025, comprising 15 trials and 7,427 participants, found a reduction in the incidence of antibiotic-associated diarrhea in groups treated with probiotics. The effect appeared particularly evident with some multispecies formulations, although heterogeneity among the protocols remains a factor to consider.
However, not all probiotics are equivalent. The available evidence identifies specific strains, including Lacticaseibacillus rhamnosus GG and Saccharomyces boulardii, as studied options for the prevention of antibiotic-associated diarrhea.
The general principle is therefore one of microbiological precision: it is not enough to know that a product contains “probiotics”; it is necessary to know the studied strain, the dose, and the clinical context in which it was evaluated.
Acute gastroenteritis
Acute gastroenteritis represents another widely studied area, especially in pediatric populations.
A 2026 synthesis comprising 25 randomized studies and over 9,000 participants found a possible reduction in the duration of diarrhea in children treated with probiotics, but with an overall quality of evidence judged to be very low.
A large umbrella meta-analysis published in 2026, comprising 36 meta-analyses and over 107,000 participants, also highlighted that the effects depend on the strain, dose, and duration of administration.
The overall picture therefore remains favorable in some contexts, but does not justify the idea of the uniform efficacy of any probiotic against any gastroenteritis.
Irritable bowel syndrome
In irritable bowel syndrome (IBS), the microbiota represents one of the possible elements involved in the complex interaction between the gut, immune system, metabolism, and enteric nervous system.
The overall literature suggests a possible benefit of probiotics for some IBS symptoms, particularly abdominal pain and bloating, but with marked variability among formulations and strains.
A meta-analysis of 52 randomized trials and 6,289 patients observed an increase in the overall response and an improvement in abdominal pain with probiotics. The Bifidobacterium and Lactobacillus subgroups also showed favorable signals. However, the effects varied considerably among the different probiotics.
IBS therefore represents a paradigmatic example of microbiota medicine: there is no probiotic for IBS in the abstract, but rather formulations and strains that can be studied for specific phenotypes and symptoms.
Inflammatory bowel diseases
In inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, the role of the microbiota is particularly interesting because communication between the microbiota, mucosal barrier, and immune system participates in the pathophysiology of the disease.
However, clinical research does not allow probiotics to be considered a substitute for pharmacological therapy.
An updated 2024 review comprising 45 RCTs and 22 systematic reviews found a possible benefit in inducing remission in ulcerative colitis, especially with multispecies formulations and in combination with conventional therapy. For Crohn’s disease, however, no significant benefit emerged. The overall certainty of the evidence was judged to be low.
This is an essential point: modulating the microbiota may provide support in certain contexts, but it is not equivalent to treating inflammatory bowel disease with a probiotic.
Helicobacter pylori: a possible support for eradication therapy
Helicobacter pylori infection constitutes another area in which the interaction between the microbiota and pharmacological therapy has been studied.
The most recent evidence suggests that some probiotics, used as an addition to eradication therapy, may increase the likelihood of success and reduce some unwanted gastrointestinal effects.
A 2025 network meta-analysis comprising 91 RCTs and 13,680 patients found an increase in eradication rates with the addition of probiotics to standard therapy, accompanied by a reduction in several adverse events.
A more recent review from 2026, specifically dedicated to products containing Lactobacillus, included 32 RCTs and 4,010 patients, confirming a relative increase in eradication success and a reduction in adverse events.
However, it is essential to emphasize that probiotics do not replace eradication therapy.
Celiac disease: biological interest, but no replacement of the gluten-free diet
Celiac disease is a case in which it is particularly important to avoid overly optimistic interpretations.
The microbiota may participate in modulating the immune response and transforming dietary components, and some probiotics have been studied for their possible role in improving symptoms.
A meta-analysis of six RCTs, involving a total of 279 participants, found possible improvements in gastrointestinal symptoms and an increase in bifidobacteria, but the certainty of the evidence was very low to low.
Therefore, speaking of probiotics capable of “improving gluten tolerance” or protecting against celiac autoimmunity would be excessive given the available evidence.
In celiac disease, a strictly gluten-free diet remains the cornerstone of management; any probiotics should be considered, if indicated, exclusively as possible support.
Microbiota, metabolism, and lipid profile
The relationship between the gut microbiota and metabolism represents one of the most interesting areas of contemporary research.
Some probiotics may interact with bile acid metabolism, cholesterol absorption, and SCFA production. These mechanisms provide a plausible connection between the microbiota and lipid metabolism.
A 2026 meta-analysis comprising 155 RCTs and 9,906 participants found average reductions in triglycerides, total cholesterol, and LDL-C, and a modest increase in HDL-C. However, the authors emphasize that the magnitude of the effect varies among studies and formulations.
The possible effect on the lipid profile should therefore be interpreted as complementary to diet, physical activity, and any prescribed therapies.
Obesity and body composition
The relationship between the microbiota and adiposity has fueled great scientific interest, but also many commercial simplifications.
Some RCTs have highlighted favorable effects of specific strains. For example, a randomized study of Bifidobacterium breve BBr60 in 75 overweight or obese adults observed, after 12 weeks, favorable changes in weight and BMI compared to placebo, along with changes in the metabolic profile and microbiota.
However, when the entire literature is analyzed, the picture becomes more cautious. A 2026 meta-analysis of 10 RCTs and 633 participants did not find a statistically significant reduction in body weight, although it observed possible reductions in BMI and fat mass.
Another 2026 meta-analysis, focused on Lactiplantibacillus plantarum, found a modest reduction in body weight and waist circumference, without significant overall effects on several metabolic markers.
The most accurate conclusion is therefore that some strains can produce modest changes in body composition, but there is no probiotic universally proven as a treatment for obesity.
Respiratory health and the gut-lung axis
The idea that the gut microbiota can communicate with the immune system of the respiratory tract has led to the development of the concept of the gut-lung axis.
However, the most recent literature calls for avoiding generalizations. A 2026 network meta-analysis found different effects depending on the genus and combination used, with possible reductions in the duration of cough or illness, but with varying levels of certainty.
Therefore, in this case as well, the correct question is not “do probiotics work for respiratory infections?”, but which strain, in which population, and for which clinical objective was it studied?
Cardiovascular health: small effects, not a therapy
Modulating the microbiota can influence lipid metabolism, inflammation, and some metabolic parameters associated with cardiovascular risk.
A 2026 meta-analysis comprising 155 RCTs found small average improvements in total cholesterol, LDL-C, triglycerides, and HDL-C.
In patients with ischemic heart disease, another meta-analysis of RCTs observed reductions in LDL-C, total cholesterol, and some metabolic and inflammatory markers.
These results are biologically interesting, but they do not mean that probiotics have been shown to prevent heart attack, stroke, or cardiovascular mortality. The effect on biomarkers must not automatically be translated into an effect on clinical events.
The choice of probiotic is more important than the number of strains
One of the most important lessons from microbiota research is that “probiotic” does not identify a single biologically or clinically homogeneous category.
The difference between genus, species, strain, dose, duration, administration matrix, and subject characteristics can significantly modify the response.
For this reason, the choice of a probiotic should start with the objective: which disorder do you want to address, which strain has been studied for that condition, at what dose, and for how long?
The total amount of CFU reported on the label alone does not constitute a guarantee of efficacy.
From the microbiota to precision medicine
The future of probiotic research does not seem to be identifying a single “universal probiotic,” but rather understanding the interaction between the strain, the host microbiota, diet, metabolism, immune system, and clinical phenotype ever better.
This perspective brings intestinal microbiology closer to personalized medicine.
The same formulation can produce a different response in different people because the baseline microbiota, diet, age, use of medications, intestinal transit, and the host's immunometabolic characteristics can alter the ecosystem in which the probiotic is introduced.
For this reason, research is gradually moving from the question “Which probiotic is best?” to a more sophisticated question: Which microbiota-targeted intervention is most appropriate for that person, in that condition, and for that specific goal?
This is a substantial difference. It means considering the microbiota not as a simple list of bacteria to increase or decrease, but as a functional ecosystem, in which the interaction between microorganisms and the host organism matters.
Evidence before marketing
Probiotic research is now sufficiently extensive to show that there are promising clinical applications, supported in some cases by randomized studies and meta-analyses.
At the same time, the same research shows why it is not correct to generically attribute the same benefits to all probiotics.
The most compelling evidence concerns some specific contexts, such as the prevention of antibiotic-associated diarrhea with certain strains, some gastrointestinal disorders, and, as support for conventional therapy, the eradication of H. pylori. In other areas, such as obesity, celiac disease, respiratory infections, or metabolism, the results are more heterogeneous and require an even more rigorous selection.
Therefore, the probiotic should not be chosen based on the number of species declared on the label or the promise to “rebalance the microbiota.” The quality of the evidence must precede the choice of product.
The most interesting frontier is precisely this: to transform knowledge of the microbiota into an increasingly precise strategy, in which the probiotic is not considered simply as a generic supplement, but as a biological tool whose usefulness must be evaluated in relation to strain, dose, duration, person, and goal.
PRODUCT_ITEM
NOTE: The information in the product sheets on this site is for informational and educational purposes only and does not represent medical advice. The published content is not intended to replace the relationship with a doctor or any medical indications, diagnoses, or prescriptions. The information provided describes the ingredients and characteristics of dietary supplements, intended to support the balance and well-being of the organism within a healthy lifestyle. Dietary supplements are not medicines and must not be used to prevent, diagnose, treat, or alleviate diseases or pathological conditions.
Scientific bibliography
1. Ding F, et al. Efficacy in bowel movement and change of gut microbiota on adult functional constipation patients treated with probiotics-containing products: a systematic review and meta-analysis. BMJ Open. 2024;14.
2. Probiotic use reduces the incidence of antibiotic-associated diarrhea among adult patients: a meta-analysis. 2025.
3. Efficacy of probiotics, prebiotics and synbiotics in irritable bowel syndrome: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. 2023.
4. Estevinho MM, et al. Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials. United European Gastroenterology Journal. 2024.
5. Efficacy of probiotics regimens for Helicobacter pylori eradication: A systematic review, pairwise, and network meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN. 2025;65:424-444.
6. Effectiveness of Lactobacillus-supplemented eradication therapy for Helicobacter pylori: a systematic review and meta-analysis of randomized controlled trials. 2026.
7. Probiotics for Celiac Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2020.
8. Effects of probiotic intervention on serum lipid profiles: current evidence from systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Food Science and Nutrition. 2026.
9. Bai Z, et al. Gut Microbiome and Metabolome Alterations in Overweight or Obese Adult Population after Weight-Loss Bifidobacterium breve BBr60 Intervention: A Randomized Controlled Trial. International Journal of Molecular Sciences. 2024.
10. Effects of probiotics and synbiotics on body weight management in individuals with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. 2026.
11. Comparative efficacy and safety of probiotic for respiratory tract infections in children: a network meta-analysis. 2026.
12. Probiotics for treating acute diarrhea in children: an evidence synthesis. 2026.
13. Impact of Probiotics on Children with Acute Gastroenteritis: Results from an Umbrella Meta-Analysis. 2026.
